These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 36760690)

  • 1. Short-term effects of intravitreal anti-vascular endothelial growth factor agents on body weight and multiple systems after treatment for retinopathy of prematurity.
    Chen J; Hao Q; Zhang J; Du Y; Chen H; Cheng X
    Front Pediatr; 2022; 10():1077137. PubMed ID: 36760690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
    Sankar MJ; Sankar J; Chandra P
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD009734. PubMed ID: 29308602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in systemic vascular endothelial growth factor levels after intravitreal injection of aflibercept in infants with retinopathy of prematurity.
    Huang CY; Lien R; Wang NK; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC; Wu WC
    Graefes Arch Clin Exp Ophthalmol; 2018 Mar; 256(3):479-487. PubMed ID: 29290015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of intravitreal bevacizumab for retinopathy of prematurity on weight gain.
    Obata S; Ichiyama Y; Matsumoto R; Kakinoki M; Saishin Y; Yanagi T; Maruo Y; Ohji M
    PLoS One; 2021; 16(12):e0261095. PubMed ID: 34890432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Bevacizumab, Ranibizumab, and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity in Turkey.
    Gunay M; Sukgen EA; Celik G; Kocluk Y
    Curr Eye Res; 2017 Mar; 42(3):462-469. PubMed ID: 27420302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RATES AND RISK FACTORS FOR RECURRENCE OF RETINOPATHY OF PREMATURITY AFTER LASER OR INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR MONOTHERAPY.
    Ling KP; Liao PJ; Wang NK; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC; Wu WC
    Retina; 2020 Sep; 40(9):1793-1803. PubMed ID: 31800460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repeated intravitreal ranibizumab for reactivated retinopathy of prematurity after intravitreal ranibizumab monotherapy: vascular development analysis.
    Xia F; Lyu J; Peng J; Zhao P
    Graefes Arch Clin Exp Ophthalmol; 2022 Sep; 260(9):2837-2846. PubMed ID: 35438363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of clinical outcomes of intravitreal ranibizumab and aflibercept treatment for retinopathy of prematurity.
    Sukgen EA; Koçluk Y
    Graefes Arch Clin Exp Ophthalmol; 2019 Jan; 257(1):49-55. PubMed ID: 30397793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum Vascular Endothelial Growth Factor Levels before and after Intravitreous Ranibizumab Injection for Retinopathy of Prematurity.
    Chen X; Zhou L; Zhang Q; Xu Y; Zhao P; Xia H
    J Ophthalmol; 2019; 2019():2985161. PubMed ID: 31236289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aqueous cytokine levels associated with severity of type 1 retinopathy of prematurity and treatment response to ranibizumab.
    Lyu J; Zhang Q; Jin H; Xu Y; Chen C; Ji X; Zhang X; Rao Y; Zhao P
    Graefes Arch Clin Exp Ophthalmol; 2018 Aug; 256(8):1469-1477. PubMed ID: 29948178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes and prognostic factors for aggressive posterior retinopathy of prematurity following initial treatment with intravitreal ranibizumab.
    Tong Q; Yin H; Zhao M; Li X; Yu W
    BMC Ophthalmol; 2018 Jun; 18(1):150. PubMed ID: 29940900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum vascular endothelial growth factor, insulin-like growth factor-1 and aflibercept levels in retinopathy of prematurity.
    Furuncuoglu U; Vural A; Kural A; Onur IU; Yigit FU
    Jpn J Ophthalmol; 2022 Mar; 66(2):151-158. PubMed ID: 35091863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Intravitreal Aflibercept vs Laser Photocoagulation on Treatment Success of Retinopathy of Prematurity: The FIREFLEYE Randomized Clinical Trial.
    Stahl A; Sukgen EA; Wu WC; Lepore D; Nakanishi H; Mazela J; Moshfeghi DM; Vitti R; Athanikar A; Chu K; Iveli P; Zhao F; Schmelter T; Leal S; Köfüncü E; Azuma N;
    JAMA; 2022 Jul; 328(4):348-359. PubMed ID: 35881122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ranibizumab injection and laser photocoagulation to treat type 1 retinopathy of prematurity after 40 weeks post menstrual age: a retrospective case series study.
    Lyu J; Zhang Q; Chen C; Xu Y; Ji X; Zhao P
    BMC Ophthalmol; 2019 Feb; 19(1):60. PubMed ID: 30808338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SHORT-TERM OUTCOMES AFTER INTRAVITREAL INJECTIONS OF CONBERCEPT VERSUS RANIBIZUMAB FOR THE TREATMENT OF RETINOPATHY OF PREMATURITY.
    Jin E; Yin H; Li X; Zhao M
    Retina; 2018 Aug; 38(8):1595-1604. PubMed ID: 28699927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retinal Detachment after Treatment of Retinopathy of Prematurity with Laser versus Intravitreal Anti-Vascular Endothelial Growth Factor.
    Barry GP; Yu Y; Ying GS; Tomlinson LA; Lajoie J; Fisher M; Binenbaum G;
    Ophthalmology; 2021 Aug; 128(8):1188-1196. PubMed ID: 33387554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular endothelial growth factor plasma levels before and after treatment of retinopathy of prematurity with ranibizumab.
    Zhou Y; Jiang Y; Bai Y; Wen J; Chen L
    Graefes Arch Clin Exp Ophthalmol; 2016 Jan; 254(1):31-6. PubMed ID: 25851862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SERUM VASCULAR ENDOTHELIAL GROWTH FACTOR AFTER BEVACIZUMAB OR RANIBIZUMAB TREATMENT FOR RETINOPATHY OF PREMATURITY.
    Wu WC; Shih CP; Lien R; Wang NK; Chen YP; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC
    Retina; 2017 Apr; 37(4):694-701. PubMed ID: 27467377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long term results of three anti-vascular endothelial growth factor agents in pachychoroid neovasculopathy.
    Karasu B; Akbas YB; Kaskal M; Aykut A; Celebi ARC
    Cutan Ocul Toxicol; 2022 Jun; 41(2):145-154. PubMed ID: 35579866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Appropriate dose of intravitreal ranibizumab for ROP: a retrospective study.
    Chen Y; Wang S; Chen S; Chen X; Han L; Zhong Q; Zhang K
    BMC Ophthalmol; 2022 Jun; 22(1):271. PubMed ID: 35729540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.